Summary

The Global Mitral Valve (Stenosis & Regurgitation) Treatment Market is projected to reach USD 16,499.08 million by 2030, expanding at a CAGR of 8.48% during the 2025-2035 forecast period. The two most common forms of mitral valve disease are mitral stenosis, where the valve becomes narrowed, and mitral regurgitation, where it fails to close properly and allows blood to leak backward.

Growing Patient Preference for Minimally Invasive Procedures
A strong shift toward patient-centric care is driving demand for minimally invasive and non-sternotomy treatments in mitral valve disease management. In fact, about 90% of patients who are eligible for this type of treatment prefer to have their valve repaired rather than replaced. And the reason behind this is repairing the valve can lead to better long-term results and help keep the heart functioning properly.

Detailed Segment Breakdown
Pathological Condition
- Mitral Stenosis: Constricted valve limits atrial-ventricular blood flow.
- Mitral Regurgitation: Valve dysfunction causes backward blood movement.
Etiology (Stenosis)
- Rheumatic Mitral Stenosis: Rheumatic disease scars and narrows valve.
- Calcified (Non-Rheumatic) Mitral Stenosis: Calcium buildup restricts valve mobility.
Treatment (Stenosis)
- Stenosis Medications: Medicines control symptoms and prevent complications.
- Mitral Valve Repair Surgery: Repair maintains native valve structure.
- Mitral Valve Replacement Surgery: Replacement ensures restored valve functionality.
- Transcatheter Balloon Valvotomy: Balloon catheter widens stenotic mitral valve.
- Transcatheter Mitral Valve Repair & Replacement: Catheter-based valve repair and replacement solutions.
Etiology (Regurgitation)
- Calcified Mitral Regurgitation (MAC): Calcified annulus leads to valve leakage.
- Non-Calcified Mitral Regurgitation: Valve leaflet abnormalities cause regurgitation.
Treatment (Regurgitation)
- Regurgitation Medications: Drug therapy stabilizes heart and symptoms.
- Repair Surgery for Regurgitation: Surgical correction improves valve performance.
- Replacement Surgery for Regurgitation: Valve prosthesis resolves severe regurgitation.
- Balloon Valvotomy for Regurgitation: Interventional balloon technique enhances valve opening.
- Transcatheter Repair/Replacement for Regurgitation: Minimally invasive treatment for advanced regurgitation.

Regional Market Overview
Some regions, like North America and Europe, are ahead of the curve when it comes to treating mitral valve disease. They have good healthcare systems, a large older population, and are quick to adopt new, less invasive technologies. On the other hand, Asia, South America, and the Middle East are just starting to catch up. They're improving their healthcare systems, and more people are getting access to advanced treatments.

Breakthrough Data for Minimally Invasive Mitral Valve Therapy
Medtronic, recently shared some promising results about its Intrepid TMVR system. This system is a type of minimally invasive treatment for mitral valve disease. The results showed that patients who used this system had good long-term outcomes, with stable valves, minimal leakage, and improved heart function. This is exciting news for people with mitral valve disease, as it could mean a new, effective treatment option.

Rising Disease Burden Driving Treatment Demand
Mitral valve disorders, like stenosis and regurgitation, are becoming more common and are contributing to heart problems worldwide. These conditions can restrict blood flow in the heart, leading to symptoms like fatigue, shortness of breath, and even severe heart failure if left untreated. It's essential to diagnose and treat these conditions quickly to prevent complications.

Key Report Attributes
- Market Size 2024: USD 6,750.71 Million
- Market Size 2030: USD 16,499.08 Million
- CAGR (2025-2035): 8.48%
- Base Year: 2024
- Market Forecast Period: 2025-2035

Industry Segmentations Growth
- By Pathological Condition: Mitral Stenosis - 5.61%, Mitral Regurgitation - 8.83%.
- By Etiology (Stenosis): Rheumatic Mitral Stenosis - 5.15%, Calcified (Non-Rheumatic) Mitral Stenosis - 5.79%.
- By Treatment (Stenosis): Medications - 5.02%, Surgery - 6.12%.
- By Etiology (Regurgitation): Calcified Mitral Regurgitation (Including Mitral Annular Calcification MAC) - 9.15%, Non-Calcified Mitral Regurgitation - 8.60%.
- By Treatment (Regurgitation): Medications - 8.18%, Surgery - 9.41%.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ..... 27
2 MARKET INTRODUCTION ...... 28
2.1 DEFINITION ...... 28
2.2 SCOPE OF THE STUDY ....... 28
2.3 RESEARCH OBJECTIVE ..... 28
2.4 MARKET STRUCTURE ....... 29
3 GLOBAL MITRAL VALVE (STENOSIS & REGURGITATION) TREATMENT MARKET, BY
PATHOLOGICAL CONDITION ...... 31
3.1 OVERVIEW ..... 31
3.2 MITRAL STENOSIS ..... 34
3.3 MITRAL REGURGITATION ..... 34
4 GLOBAL MITRAL VALVE STENOSIS TREATMENT MARKET, BY ETIOLOGY ...... 35
4.1 OVERVIEW ..... 35
4.2 RHEUMATIC MITRAL STENOSIS ..... 37
4.3 CALCIFIED (NON-RHEUMATIC) MITRAL STENOSIS ..... 38
5 GLOBAL MITRAL VALVE STENOSIS TREATMENT MARKET, BY TREATMENT ...... 39
5.1 OVERVIEW ..... 39
5.2 MEDICATIONS ....... 42
5.3 SURGERY ..... 42
5.3.1 MITRAL VALVE REPAIR SURGERY ..... 44
5.3.2 MITRAL VALVE REPLACEMENT SURGERY ..... 44
5.3.3 TRANSCATHETER BALLOON VALVOTOMY ....... 45
5.3.4 TRANSCATHETER MITRAL VALVE REPAIR & REPLACEMENT ....... 45
6 GLOBAL MITRAL VALVE REGURGITATION TREATMENT MARKET, BY ETIOLOGY ....... 46
6.1 OVERVIEW ..... 46
6.2 CALCIFIED MITRAL REGURGITATION (INCLUDING MITRAL ANNULAR CALCIFICATION MAC) . 49
6.3 NON-CALCIFIED MITRAL REGURGITATION ..... 50
7 GLOBAL MITRAL VALVE REGURGITATION TREATMENT MARKET, BY TREATMENT ...... 51
7.1 OVERVIEW ..... 51
7.2 MEDICATIONS ....... 54
7.3 SURGERY ..... 55
7.3.1 MITRAL VALVE REPAIR SURGERY ..... 56
7.3.2 MITRAL VALVE REPLACEMENT SURGERY ..... 57
7.3.3 TRANSCATHETER BALLOON VALVOTOMY ....... 57
7.3.4 TRANSCATHETER MITRAL VALVE REPAIR & REPLACEMENT ....... 58
8 GLOBAL MITRAL VALVE (STENOSIS & REGURGITATION) TREATMENT MARKET, BY REGION
59
8.1 OVERVIEW ..... 59
8.2 NORTH AMERICA ....... 61
8.2.1 US...... 72
8.2.2 CANADA ..... 78
8.3 EUROPE ..... 85
8.3.1 GERMANY ...... 95
8.3.2 FRANCE ...... 101
8.3.3 UK ..... 107
8.3.4 ITALY ....... 114
8.3.5 SPAIN ...... 120
8.3.6 RUSSIA ....... 126
8.3.7 REST OF EUROPE ..... 132
8.4 ASIA-PACIFIC ...... 139
8.4.1 CHINA ...... 148
8.4.2 INDIA ....... 154
8.4.3 JAPAN ..... 159
8.4.4 SOUTH KOREA ...... 165
8.4.5 MALAYSIA ..... 170
8.4.6 THAILAND ...... 176
8.4.7 INDONESIA ..... 181
8.4.8 REST OF ASIA-PACIFIC ..... 188
8.5 SOUTH AMERICA ....... 194
8.5.1 BRAZIL ..... 203
8.5.2 MEXICO ...... 209
8.5.3 ARGENTINA ...... 215
8.5.4 REST OF SOUTH AMERICA ...... 220
8.6 MIDDLE EAST & AFRICA ...... 226
8.6.1 GCC COUNTRIES...... 235
8.6.2 SOUTH AFRICA ..... 240
8.6.3 REST OF MIDDLE EAST & AFRICA ..... 246
9 COMPETITIVE LANDSCAPE ..... 253
9.1 INTRODUCTION ..... 253
9.2 MARKET SHARE ANALYSIS, 2024 ..... 253
9.3 COMPETITOR DASHBOARD....... 254
9.4 PUBLIC PLAYERS STOCK SUMMARY ..... 255
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ...... 255
9.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ..... 256
9.1.1 PRODUCT LAUNCH ..... 256
9.1.2 PARTNERSHIP ...... 256
9.1.3 ACQUISITION ....... 256
10 COMPANY PROFILES ...... 260
10.1 MEDTRONIC ..... 260
10.1.1 COMPANY OVERVIEW ....... 260
10.1.2 FINANCIAL OVERVIEW ...... 261
10.1.3 PRODUCTS OFFERED ..... 262
10.1.4 KEY DEVELOPMENTS ..... 262
10.1.5 SWOT ANALYSIS ..... 263
10.1.6 KEY STRATEGIES ..... 263
10.2 NOVARTIS AG ..... 264
10.2.1 COMPANY OVERVIEW ....... 264
10.2.2 FINANCIAL OVERVIEW ...... 265
10.2.3 PRODUCTS OFFERED ..... 266
10.2.4 KEY DEVELOPMENTS ..... 266
10.2.5 SWOT ANALYSIS ..... 267
10.2.6 KEY STRATEGIES ..... 267
10.3 TEVA PHARMACEUTICAL INDUSTRIES LTD ...... 268
10.3.1 COMPANY OVERVIEW ....... 268
10.3.2 FINANCIAL OVERVIEW ...... 269
10.3.3 PRODUCTS OFFERED ..... 270
10.3.4 KEY DEVELOPMENTS ..... 270
10.3.5 SWOT ANALYSIS ..... 271
10.3.6 KEY STRATEGIES ..... 271
10.4 VALCARE MEDICAL ...... 272
10.4.1 COMPANY OVERVIEW ....... 272
10.4.2 FINANCIAL OVERVIEW ...... 273
10.4.3 PRODUCT OFFERED ....... 273
10.4.4 KEY DEVELOPMENTS ..... 273
10.4.5 KEY STRATEGIES ..... 274
10.5 AFFLUENT MEDICAL ...... 275
10.5.1 COMPANY OVERVIEW ....... 275
10.5.2 FINANCIAL OVERVIEW ...... 276
10.5.3 PRODUCTS OFFERED ..... 276
10.5.4 KEY DEVELOPMENTS ..... 276
10.5.5 KEY STRATEGIES ..... 276
10.6 ABBOTT ..... 278
10.6.1 COMPANY OVERVIEW ....... 278
10.6.2 FINANCIAL OVERVIEW ...... 279
10.6.3 PRODUCTS OFFERED ..... 280
10.6.4 KEY DEVELOPMENTS ..... 280
10.6.5 SWOT ANALYSIS ..... 281
10.6.6 KEY STRATEGIES ..... 282
10.7 BAYER AG ...... 283
10.7.1 COMPANY OVERVIEW ....... 283
10.7.2 FINANCIAL OVERVIEW ...... 284
10.7.3 PRODUCTS OFFERED ..... 285
10.7.4 KEY DEVELOPMENTS ..... 285
10.7.5 SWOT ANALYSIS ..... 285
10.7.6 KEY STRATEGY ..... 286
10.8 EDWARDS LIFESCIENCES CORPORATION ...... 287
10.8.1 COMPANY OVERVIEW ....... 287
10.8.2 FINANCIAL OVERVIEW ...... 288
10.8.3 PRODUCTS OFFERED ..... 288
10.8.4 KEY DEVELOPMENTS ..... 289
10.8.5 KEY STRATEGY ..... 290
10.9 ARTIVION, INC. ...... 291
10.9.1 COMPANY OVERVIEW ....... 291
10.9.2 FINANCIAL OVERVIEW ...... 292
10.9.3 PRODUCTS OFFERED ..... 292
10.9.4 KEY DEVELOPMENTS ..... 293
10.9.5 KEY STRATEGY ..... 293
10.10 CORCYM GROUP ....... 294
10.10.1 COMPANY OVERVIEW ....... 294
10.10.2 FINANCIAL OVERVIEW ...... 294
10.10.3 PRODUCTS OFFERED ..... 295
10.10.4 KEY DEVELOPMENTS ..... 295
10.10.5 KEY STRATEGY ..... 295
11 RESEARCH METHODOLOGY ...... 297
11.1 OVERVIEW ..... 297
11.2 DATA FLOW ...... 299
11.2.1 DATA MINING PROCESS ...... 299
11.3 PURCHASED DATABASE: ..... 300
11.4 SECONDARY SOURCES: ..... 301
11.4.1 SECONDARY RESEARCH DATA FLOW: ....... 302
11.5 PRIMARY RESEARCH: ..... 303
11.5.1 PRIMARY RESEARCH DATA FLOW: ..... 304
11.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ....... 305
11.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ..... 305
11.6 APPROACHES FOR MARKET SIZE ESTIMATION: ....... 306
11.6.1 REVENUE ANALYSIS APPROACH ...... 306
11.7 DATA FORECASTING....... 307
11.7.1 DATA FORECASTING TYPE ...... 307
11.8 DATA MODELING ..... 308
11.8.1 MICROECONOMIC FACTOR ANALYSIS: ...... 308
11.8.2 DATA MODELING: ....... 309
11.9 TEAMS AND ANALYST CONTRIBUTION ..... 311
12 DATA CITATIONS ....... 313